RBI Aktienanleihe AZ2 26.03.2025/ AT0000A37G10 /
11/06/2024 09:19:51 | Chg.-0.100 | Bid12:23:07 | Demandez à12:23:07 | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
111.500EUR | -0.09% | 111.570 Bid taille: 50,000 |
111.820 Ask la taille: 50,000 |
ANDRITZ AG | 49.00 EUR | 26/03/2025 | Call |
GlobeNewswire
12:39
SQUARESPACE ALERT: Is $44 Per Share Too Low for Squarespace (NYSE: SQSP)? BFA Law is Investigating a...
GlobeNewswire
12:36
SPROUT SOCIAL NOTICE: If You Suffered Losses on Your Sprout Social (Nasdaq: SPT) Investment, You are...
GlobeNewswire
12:33
POWERSCHOOL ALERT: Is $22.80 Per Share Too Low for PowerSchool (NYSE: PWSC)? BFA Law is Investigatin...
GlobeNewswire
12:31
UIPATH NOTICE: If You Suffered Losses When UiPath, Inc.’s (NYSE: PATH) Stock Dropped 34%, You are Re...
GlobeNewswire
12:30
Park Hotels & Resorts Announces Second Quarter 2024 Earnings Conference Call on August 1, 2024
GlobeNewswire
12:30
Fastly ALERT: Securities Fraud Lawsuit Could Allow Investors to Recover Losses; Block & Leviton Enco...
GlobeNewswire
12:28
CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urg...
GlobeNewswire
12:00
Liberty Gold Announces Approval of the Fourth Plan of Operations Amendment, Black Pine Oxide Gold Pr...
GlobeNewswire
12:00
RadNet, Inc. to Present at the Sidoti & Company 2024 Small Cap Conference on Wednesday, June 12th
GlobeNewswire
12:00
SiteMinder and Cloudbeds partner to create new distribution and revenue opportunities for hotels
GlobeNewswire
12:00
Digihost Expands Bitcoin Mining Operations with 11,000 S21s Increasing Hashing Rate to 3.2 EH/s
GlobeNewswire
12:00
Kepler Validates SDA-Compatible Optical Technology For Space Data Relay Constellation
GlobeNewswire
12:00
FreedomPay Launches Industry’s First Independent Payment Processing Referral Advisory for Merchants
GlobeNewswire
12:00
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support in...
GlobeNewswire
12:00
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page